Skip to main content

Table 5 Number of patients (%) with the most commonly reported adverse events in the maintenance treatment phase (≥2 % in any treatment group; safety population)

From: Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease

  Patients [n (%)]
  On-demand (n = 301) Continuous (n = 294a)
Flatulence 15 (5.0) 12 (4.1)
Abdominal pain 10 (3.3) 9 (3.1)
Diarrhea 6 (2.0) 9 (3.1)
Constipation 9 (3.0) 5 (1.7)
Viral infection 12 (4.0) 8 (2.7)
Headache 5 (1.7) 7 (2.4)
Respiratory infection 7 (2.3) 6 (2.0)
Gastroenteritis 7 (2.3) 9 (3.1)
Back pain 5 (1.7) 7 (2.4)
Arthralgia 2 (0.7) 6 (2.0)
  1. aThree patients did not take any study drug and were therefore excluded from the safety population